NASDAQ:AQST

Aquestive Therapeutics Stock News

Healthcare > Drug Manufacturers - Specialty & Generic

Buy AQST

*Your capital is at risk

$4.03

+0.100 (+2.54%)

At Close: Jun 03, 2026

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

08:30am, Friday, 27'th Sep 2024

WARREN, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful im

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

08:15am, Monday, 09'th Sep 2024

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful im

Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings

11:37pm, Thursday, 22'nd Aug 2024

Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitabilit

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

08:00am, Thursday, 22'nd Aug 2024

WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

04:12am, Tuesday, 20'th Aug 2024

Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with

Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript

02:37pm, Wednesday, 07'th Aug 2024

Aquestive Therapeutics Inc. (NASDAQ:AQST ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executiv

Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

07:36pm, Tuesday, 06'th Aug 2024

Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare wit

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

06:37pm, Tuesday, 06'th Aug 2024

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago.

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

04:22pm, Tuesday, 06'th Aug 2024

WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

08:00am, Thursday, 25'th Jul 2024

WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

08:00am, Tuesday, 23'rd Jul 2024

WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful imp

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by